The next generation of advanced pharmaceutical technologies holds great potential and could fuel extraordinary growth in the $60 billion global drug delivery market. Rainbow Coral’s biotech subsidiary, Rainbow BioSciences, aims to be right in the middle of the action.
Some pharmaceutical giants believe new drug delivery methods will serve as a crucial growth generator, and new innovations are constantly taking place across the healthcare sector. Many experts believe that personalized medicine is the future of healthcare, and customized drug delivery has the potential to drastically change the way value is assessed and compensated in the U.S. healthcare system.
Rainbow Coral is diligently positioning itself to capitalize on the evolving drug-delivery paradigm by partnering with key players in the field. The company is now in talks with an emerging company that owns technology with the potential to enable selective, site-specific delivery, allowing for lower drug concentrations and greatly reducing the risk of drug toxicity. In addition to helping millions of patients struggling with chronic conditions, this bold new technology can also extend the patent life cycles of drugs, giving potential pharmaceutical partners a tremendous market advantage.
For more information, visit www.RainbowBioSciences.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment